| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-12-01 | Eisai (Japan) | Eisai China Holdings | establishement of a holding company in China |
Services contract | ||
| 2014-11-30 | Philips (The Netherlands) Image Stream Medical (USA - MA) | image-guided minimally invasive therapies | collaboration |
Technology - Services | Collaboration agreement | |
| 2014-11-28 | Eisai (Japan) | new production facility for parenteral manufacturing | construction of new premises |
Construction of new premises | ||
| 2014-11-27 | GamaMabs Pharma (France) Mayo Clinic (USA - MN) | 3C23K antibody | ovarian cancer | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2014-11-27 | Quantum Genomics (France) | chief medical officer | nomination | Cardiovascular diseases | Nomination | |
| 2014-11-27 | L\'Oréal (France) Nestlé (Switzerland) | Inneov | termination |
Termination of the agreement | ||
| 2014-11-27 | Eisai (Japan) | new packaging facility at the Hatfield production plant | opening of new premises | CNS diseases - Neurological diseases | Opening of new premises | |
| 2014-11-26 | Bone Therapeutics (Belgium) | chief financial officer | nomination | Bone diseases - Regenerative medicine | Nomination | |
| 2014-11-25 | Santhera Pharmaceuticals (Switzerland) Parent Project Muscular Dystrophy (USA - NJ) | Catena®/Raxone® (idebenone) | Duchenne Muscular Dystrophy | clinical research |
Genetic diseases - Neuromuscular diseases - Rare diseases | Clinical research agreement |
| 2014-11-24 | BMS (USA - NY) Five Prime Therapeutics (USA - CA) | Opdivo® (nivolumab) and FPA008 | non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, pancreatic cancer, colorectal cancer, malignant glioma | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2014-11-24 | Lundbeck (Denmark) | resignation |
Resignation | |||
| 2014-11-24 | Novo Nordisk (Denmark) | resignation |
Joint-venture agreement | |||
| 2014-11-24 | MRC Technology (UK) Yabao Pharmaceuticals (China) | compounds targeting a specific kinase involved in neurodegeneration | Parkinson’s disease | development commercialisation |
Neurodegenerative diseases | Development agreement |
| 2014-11-24 | Horizon Discovery Group (UK) Adarza BioSystems (USA - MO) | Arrayed Imaging Reflectometry (AIR™) | licensing supply |
Technology - Services | Licensing agreement | |
| 2014-11-24 | Newlink Genetics (USA - IO) Merck&Co (USA - NJ) | rVSV-EBOV (Ebola) vaccine candidate | development licensing manufacturing production |
Licensing agreement | ||
| 2014-11-24 | Janssen Biotech, a J&J company (USA - NJ) Transposagen Biopharmaceuticals (USA - KY) | allogeneic Chimeric Antigen Receptor T-cells (CAR-T) | undisclosed cancers | collaboration licensing |
Cancer - Oncology | Collaboration agreement |
| 2014-11-22 | AstraZeneca (UK) | expansion of a manufacturing plant |
Construction of new premises | |||
| 2014-11-21 | Stallergenes (France) Actogenix (Belgium) | oral first-in-class treatments of allergic diseases based on ActoBiotics™ | allergic diseases | development |
Allergic diseases - Immunological diseases | Exercise of an option agreement |
| 2014-11-20 | Amgen (USA - CA) | opening of new biomanufacturing facilities |
Opening of new premises | |||
| 2014-11-20 | Abbvie (USA - IL) | plant acquisition |
Plant acquisition |
